A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
--------------------------------------------------------------------
Source: CNBC
Published: 2026-05-31 22:00 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Asia, China, Law & Courts, Drugs, World News, Crime & Justice, Asia Pacific
--------------------------------------------------------------------
Snippet:
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial, according to results released Sunday.
--------------------------------------------------------------------